Comparing Organigram Global (NASDAQ:OGI) & Avita Medical (NASDAQ:RCEL)

Organigram Global (NASDAQ:OGI) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Insider and Institutional Ownership

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 27.7% of Avita Medical shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Comparatively, 2.2% of Avita Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Organigram Global and Avita Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1	0	2	0	2.33
Avita Medical	1	1	5	0	2.57

Avita Medical has a consensus target price of $12.20, indicating a potential downside of 9.02%. Given Avita Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Avita Medical is more favorable than Organigram Global.

Profitability

This table compares Organigram Global and Avita Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	28.14%	-13.39%	-8.67%
Avita Medical	-56.96%	N/A	-78.53%

Risk and Volatility

Organigram Global has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.

Valuation & Earnings

This table compares Organigram Global and Avita Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07 million	0.71	-$17.70 million	$0.46	2.03
Avita Medical	$71.61 million	5.76	-$48.59 million	($1.44)	-9.31

Organigram Global has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

Summary

Avita Medical beats Organigram Global on 7 of the 13 factors compared between the two stocks.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

About Avita Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.